Aspira Pathlab & Diagnostics Ltd (540788)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 7 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 6 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Aspira Pathlab & Diagnostics Ltd reported Q2 FY27 results on 7 Nov 2026: revenue ₹6.3 Cr (-22.6% year on year, +1.5% on the previous quarter), and net profit ₹-1.2 Cr (against a profit a year earlier); the operating margin was -10.8%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹6.3 | -22.6% | +1.5% |
| செயல்பாட்டு லாபம் | ₹-0.7 | நஷ்டமாக | நஷ்டமாக |
| நிகர லாபம் | ₹-1.2 | நஷ்டமாக | நஷ்டம் அதிகரித்தது |
| EPS (₹) | -1.13 | நஷ்டமாக | நஷ்டம் அதிகரித்தது |
| செயல்பாட்டு லாப வரம்பு | -10.8% | — | — |
- நஷ்டத்தில்: ஓராண்டுக்கு முன் லாபம்
- செயல்பாட்டு லாப வரம்பு 3785 bps YoY குறைந்தது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Aspira Pathlab & Diagnostics Limited held a Board Meeting on November 06, 2026, to approve its unaudited standalone financial results for the second quarter and half year ended September 30, 2026. The meeting commenced at 01:30 PM IST and concluded at 04:00 PM IST. The filing reported zero financial indebtedness across bank loans and debt securities as of September 30, 2026, with zero defaults. Detailed line-item revenue and profit figures were not included in the extracted disclosure portion.
- Board approved unaudited standalone financial results for Q2 and H1 ended September 30, 2026
- Board meeting commenced at 01:30 PM IST and concluded at 04:00 PM IST on November 06, 2026
- Total outstanding indebtedness from bank facilities and debt securities reported as 0 crore
- Total amount of default on loans or debt securities reported as 0 crore
Jay Arvind Bhanushali, belonging to the promoter/promoter group of Aspira Pathlab & Diagnostics Ltd, disclosed an open-market acquisition of 245 equity shares on September 28, 2026. Following the transaction, his holding rose marginally from 7,49,262 shares (7.28%) to 7,49,507 shares (7.28%). Given the company's total equity base of 1,02,93,000 shares, the acquisition size is immaterial (approx. Rs 25,500 at the current market price of Rs 104.3).
- Acquired 245 equity shares via open market on 28-09-2026
- Shareholding prior to acquisition was 7,49,262 shares (7.28%)
- Post-transaction holding stands at 7,49,507 shares (7.28%)
- Total voting capital of the company remains unchanged at 1,02,93,000 shares (Rs 10,29,30,000)
Jay Arvind Bhanushali, belonging to the promoter group of Aspira Pathlab & Diagnostics Ltd, disclosed the acquisition of 1,424 equity shares via the open market between September 17, 2026, and September 24, 2026. This acquisition represents approximately 0.01% of the total share capital. Following the transaction, his holding marginally increased from 7,47,838 shares (7.27%) to 7,49,262 shares (7.28%). At the current stock price of Rs 104.3, the acquired shares are valued at roughly Rs 1.48 lakh, indicating minimal financial materiality.
- Acquired 1,424 equity shares (0.013% rounded to 0.01%) via open market
- Holding increased from 7,47,838 shares (7.27%) to 7,49,262 shares (7.28%)
- Acquisition conducted between 17-09-2026 and 24-09-2026
- Total equity share capital remains unchanged at Rs 10,29,30,000 (1,02,93,000 shares of Rs 10 each)
Aspira Pathlab & Diagnostics Limited has released its Annual Report for FY 2025-26 and convened its 53rd AGM on September 25, 2026. Key special resolutions include the re-designation of Mr. Nikunj Velji Mange as Managing Director for a 5-year tenure effective August 12, 2026, and approval for material related party transactions with Yashraj Research Foundation up to Rs. 5 Crores. The accompanying ratio disclosures reflect a steep drop in FY26 operating performance, with Return on Equity falling to 0.42% (from 18.54% in FY25) and Net Profit margin dropping to 0.21% (from 9.42% in FY25).
- 53rd Annual General Meeting scheduled for September 25, 2026 via Video Conferencing.
- Proposed approval for material related party transactions with Yashraj Research Foundation up to Rs. 5 Crores.
- Re-designation of Executive Director Mr. Nikunj Velji Mange as Managing Director for 5 years from August 12, 2026.
- FY26 Return on Equity declined to 0.42% vs 18.54% in FY25, and ROCE fell to 3.24% vs 18.03% in FY25.
Aspira Pathlab & Diagnostics has issued the notice for its 53rd Annual General Meeting (AGM) scheduled for September 25, 2026. Key agenda items include the approval of material related-party transactions with Yashraj Research Foundation for an aggregate value up to ₹5 Crore (representing ~21.7% of TTM revenue of ₹23 Crore). Additionally, the company seeks shareholder approval to re-designate Executive Director Mr. Nikunj Velji Mange as Managing Director for a 5-year term effective August 12, 2026.
- 53rd Annual General Meeting scheduled for Friday, September 25, 2026, via Video Conferencing.
- Seeking shareholder approval for material related party transactions with Yashraj Research Foundation up to ₹5 Crore.
- Proposed appointment of Mr. Nikunj Velji Mange as Managing Director for 5 years with effect from August 12, 2026.
- Cut-off date for e-voting set as September 18, 2026, with remote e-voting running from September 22 to September 24, 2026.
Aspira Pathlab & Diagnostics Limited announced that its 53rd Annual General Meeting (AGM) will be held on September 25, 2026, at 2:00 PM IST via video conferencing. The company has scheduled its book closure from September 19, 2026, to September 25, 2026 (both days inclusive) for AGM purposes. The cut-off date to determine shareholder voting eligibility is September 18, 2026, with the remote e-voting window open from September 22, 2026 (9:00 AM IST) to September 24, 2026 (5:00 PM IST).
- 53rd Annual General Meeting scheduled for September 25, 2026, at 2:00 PM IST via VC/OAVM
- Book closure period fixed from September 19, 2026, to September 25, 2026 (both days inclusive)
- Remote e-voting window runs from 9:00 AM IST on September 22, 2026, to 5:00 PM IST on September 24, 2026
- Shareholder eligibility cut-off date set as September 18, 2026
Aspira Pathlab & Diagnostics has restructured its leadership, appointing Vaibhav Odhekar (co-founder of POKKT) as Additional Executive Director and re-designating Nikunj Mange as Managing Director. The board also deferred a previously proposed fund-raising agenda, deciding not to proceed at this time. These changes come as the company manages a small TTM revenue base of ₹25 Cr and thin operating margins of 5.8%. The new leadership brings significant technology and scaling experience, which is critical given the low promoter holding of 18.4%.
- Appointment of Mr. Vaibhav Odhekar, an IIM Lucknow alumnus with 20+ years of experience, as Additional Executive Director.
- Re-designation of Mr. Nikunj Velji Mange as Managing Director for a term of 5 years and 9 months.
- Board decided not to take up the fund-raising proposal in the current meeting after due deliberation.
- Appointment of M/s. Harsh Kholiya & Co as Internal Auditor for Q2, Q3, and Q4 of FY 2026-27.
- Company reported a net loss of ₹0.69 Cr in the most recent quarter (Mar 2026) on revenue of ₹6.52 Cr.
Aspira Pathlab & Diagnostics has scheduled a board meeting on August 12, 2026, to approve its Q1 FY27 financial results and evaluate a potential fundraise. The fundraise could involve equity shares, warrants, or rights issues, which is significant given the company's small market cap of Rs 114 Cr. This follows a volatile financial year where the company reported a net loss of Rs 0.69 Cr in the March 2026 quarter. Investors should note the low promoter holding of 18.39%, which makes the terms of any equity dilution particularly relevant.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
- Proposal to raise funds via equity, warrants, or rights issue to be considered.
- Promoter holding is currently low at 18.39% as of March 2026.
- Company reported a TTM revenue of Rs 25 Cr with a thin operating margin of 5.8%.
- Recent quarterly performance showed a net loss of Rs 0.69 Cr in March 2026.
As p i r a P a t h l a b & D i a g n o s t i c s L t d h a s a n n o u n c e d t h e r e s i g n a t i o n o f i t s I n t e r n a l A u d i t o r , M / s V i s h a l J B h a n u s h a l i a n d A s s o c i a t e s , e f f e c t i v e A u g u s t 1 3 , 2 0 2 6 . T h e r e s i g n a t i o n i s a t t r i b u t e d t o p r e o c c u p a t i o n a n d p e r s o n a l r e a s o n s . T h i s c o m e s a t a t i m e w h e n t h e c o m p a n y r e p o r t s a v e r y l o w T T M P A T o f R s 0 . 0 5 c r o r e a n d m a i n t a i n s a l o w p r o m o t e r h o l d i n g o f 1 8 . 4 % . I n v e s t o r s s h o u l d n o t e t h a t t h e c o m p a n y i s c u r r e n t l y t r a d i n g a t a n e x t r e m e l y h i g h P / E o f 1 9 6 9 . 2 .
- Int e r n a l A u d i t o r M / s V i s h a l J B h a n u s h a l i a n d A s s o c i a t e s t o c e a s e r o l e o n A u g u s t 1 3 , 2 0 2 6
- R e s i g n a t i o n c i t e s p r e o c c u p a t i o n a n d p e r s o n a l r e a s o n s w i t h n o o t h e r m a t e r i a l r e a s o n s p r o v i d e d
- C o m p a n y T T M r e v e n u e s t a n d s a t R s 2 5 c r o r e w i t h a m a r g i n a l n e t p r o f i t o f R s 0 . 0 5 c r o r e
- P r o m o t e r h o l d i n g r e m a i n s r e l a t i v e l y l o w a t 1 8 . 3 9 % a s o f M a r c h 2 0 2 6
Mr. Pankaj Jashwant Shah has resigned from his dual role as Managing Director and Chief Executive Officer of Aspira Pathlab & Diagnostics Ltd, effective immediately on August 03, 2026. The resignation is attributed to personal reasons. This leadership exit occurs as the company faces financial pressure, having reported a net loss of 0.69 cr in the March 2026 quarter. With a small TTM revenue base of 25 cr and low promoter holding of 18.39%, the transition to new leadership will be critical for operational stability.
- Resignation of Mr. Pankaj Jashwant Shah as MD and CEO effective August 03, 2026
- Company reported a net loss of 0.69 cr in the most recent quarter ending March 2026
- Promoter holding is relatively low at 18.39% as of the March 2026 filing
- TTM revenue stands at 25 cr with a marginal FY26 net profit of 0.05 cr
- Operating Profit Margin (OPM) remains thin at 5.8% for the trailing twelve months
Mr. Vaibhav Odhekar has resigned from his position as Additional Executive Director at Aspira Pathlab & Diagnostics Ltd, effective July 25, 2026, citing personal reasons. The company, which has a small market capitalization of ₹106 Cr, reported a net loss of ₹0.69 Cr in the March 2026 quarter. With a relatively low promoter holding of 18.39%, management stability remains a key area for monitoring in this micro-cap entity.
- Resignation of Mr. Vaibhav Odhekar effective from close of business hours on July 25, 2026
- Company reported a TTM revenue of ₹25 Cr with a marginal TTM EPS of ₹0.06
- Promoter holding has remained stagnant at 18.39% as of the March 2026 quarter
- The company recorded an operating loss of ₹0.33 Cr in the most recent quarter (March 2026)
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
